ClinicalTrials.gg
RecruitingNCT07662213Eluminate-2Updated Oct 22, 2026

A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

A Phase 3 interventional study of Elecoglipron and Semaglutide in Type 2 Diabetes Mellitus, sponsored by AstraZeneca. Recruiting at 210 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Oct 22, 2026Site recruiting status changed2 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing elecoglipron in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 6 of them phase 3. elecoglipron · Diabetes Mellitus, Type 2.

Planned enrollment
2nd of 18
1,200 · median 57
Started
2026
with 8 others
Phase 3
6 of 18
6 open now
Registered
13th of 18
by date
Lead sponsor
14 of 18
AstraZeneca

Among the 18 studies testing elecoglipron in Diabetes Mellitus, Type 2, this one is the 2nd largest by planned enrollment, is one of 9 that started in 2026, is one of 6 in phase 3, and was the 13th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 18 studies testing elecoglipron in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About elecoglipron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing elecoglipron in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with T2DM and increased cardiovascular risk that is inadequately managed alone or on stable treatment with other background glucose-lowering medication(s).

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 90 days prior to screening
  • T2DM inadequately managed with lifestyle management alone or on stable treatment with other background glucose-lowering medication(s)
  • value of ≥ 7% to ≤ 10.5% (53 to 91.3 mmol/mol)
  • Increased risk of cardiovascular (CV) events defined by ≥1 of: documented coronary heart disease, peripheral arterial disease, ischemic cerebrovascular disease, or heart failure ( II-III); or ≥2 CV risk factors
  • (BMI) of ≥ 23 kg/m2 at screening
  • Stable body weight (self-reported or documented) for 90 days prior to screening

Exclusion criteria

Exclusion Criteria:

  • Type 1 Diabetes Mellitus (T1DM), secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma
  • Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema
  • Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
  • condition affecting the upper Gastrointestinal (GI) tract or chronic use of any medication that affects gastric motility or gastric emptying
  • History of acute or chronic pancreatitis
  • Severe congestive heart failure ( IV)
  • History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,200 participants (estimated)

Study arms

  • Experimental
    Elecoglipron

    Participants will receive elecoglipron dose XX mg administered orally once daily.

    Drug: Elecoglipron

  • Active comparator
    Semaglutide

    Participants will receive semaglutide dose XX mg administered orally once daily.

    Drug: Semaglutide

Interventions

  • Elecoglipron is administered orally once daily.

  • Semaglutide is administered orally once daily.

06

What researchers measure

Primary outcomes

  1. Change from baseline in Hemoglobin A1c (HbA1c)

    Time frame: Baseline to Week 52

Secondary outcomes

  1. Percent change from baseline to Week 52 in body weight

    Time frame: Baseline to Week 52

  2. Change from baseline to Week 52 in body weight (kg)

    Time frame: Baseline to Week 52

  3. Achieved ≥ 5% weight loss from baseline at Week 52 and achieved HbA1c < 7% (53 mmol/mol) at Week 52

    Time frame: Baseline to Week 52

  4. Achieved HbA1c ≤ 6.5% (48 mmol/mol) at Week 52

    Time frame: Week 52

  5. Achieved HbA1c < 7% (53 mmol/mol) at Week 52

    Time frame: Week 52

  6. Achieved ≥ 5% weight loss from baseline at Week 52

    Time frame: Baseline to Week 52

  7. Change from baseline to Week 52 in Systolic Blood Pressure (BP) and Diastolic BP

    Time frame: Baseline to Week 52

07

Study locations

107 of 210 sites recruiting
  • Research Site
    Birmingham, Alabama 35205, United States
    Not yet recruiting
  • Research Site
    Mesa, Arizona 85213, United States
    Not yet recruiting
  • Research Site
    Phoenix, Arizona 85016, United States
    Recruiting
  • Research Site
    Tempe, Arizona 85281, United States
    Not yet recruiting
  • Research Site
    Covina, California 91723, United States
    Not yet recruiting
  • Research Site
    Encinitas, California 92024, United States
    Recruiting
  • Research Site
    Garden Grove, California 92844, United States
    Not yet recruiting
  • Research Site
    Loma Linda, California 92354, United States
    Not yet recruiting
  • Research Site
    Long Beach, California 90807, United States
    Not yet recruiting
  • Research Site
    Pomona, California 91768, United States
    Recruiting
  • Research Site
    Sacramento, California 95821, United States
    Recruiting
  • Research Site
    Bridgeport, Connecticut 06606, United States
    Not yet recruiting
  • Research Site
    Crystal River, Florida 34429, United States
    Not yet recruiting
  • Research Site
    Hollywood, Florida 33021, United States
    Not yet recruiting
  • Research Site
    Jacksonville, Florida 32209, United States
    Not yet recruiting
  • Research Site
    Lake City, Florida 32055, United States
    Recruiting
  • Research Site
    Leesburg, Florida 34748, United States
    Recruiting
  • Research Site
    Orlando, Florida 32806, United States
    Not yet recruiting
  • Research Site
    Lilburn, Georgia 30047, United States
    Not yet recruiting
  • Research Site
    Idaho Falls, Idaho 83404, United States
    Not yet recruiting
  • Research Site
    Melrose Park, Illinois 60160, United States
    Not yet recruiting
  • Research Site
    Evansville, Indiana 47710, United States
    Not yet recruiting
  • Research Site
    Ames, Iowa 50010, United States
    Recruiting
  • Research Site
    Wichita, Kansas 67226, United States
    Not yet recruiting
  • Research Site
    Bowling Green, Kentucky 42101, United States
    Not yet recruiting
  • Research Site
    Rockville, Maryland 20852, United States
    Not yet recruiting
  • Research Site
    Rockville, Maryland 20852, United States
    Recruiting
  • Research Site
    Southfield, Michigan 48076, United States
    Not yet recruiting
  • Research Site
    Minneapolis, Minnesota 55416, United States
    Not yet recruiting
  • Research Site
    Jefferson City, Missouri 65109, United States
    Not yet recruiting
  • Research Site
    Kansas City, Missouri 64114, United States
    Not yet recruiting
  • Research Site
    Omaha, Nebraska 68114, United States
    Not yet recruiting
  • Research Site
    Henderson, Nevada 89052, United States
    Recruiting
  • Research Site
    Las Vegas, Nevada 89128, United States
    Not yet recruiting
  • Research Site
    Albuquerque, New Mexico 87112, United States
    Not yet recruiting
  • Research Site
    Durham, North Carolina 27701, United States
    Not yet recruiting
  • Research Site
    Morehead City, North Carolina 28557, United States
    Recruiting
  • Research Site
    Raleigh, North Carolina 27612, United States
    Not yet recruiting
  • Research Site
    Statesville, North Carolina 28625, United States
    Not yet recruiting
  • Research Site
    Wilmington, North Carolina 28403, United States
    Recruiting
  • Research Site
    Columbus, Ohio 43215, United States
    Not yet recruiting
  • Research Site
    Oklahoma City, Oklahoma 73134, United States
    Not yet recruiting
  • Research Site
    Feasterville-Trevose, Pennsylvania 19053, United States
    Not yet recruiting
  • Research Site
    Philadelphia, Pennsylvania 19114, United States
    Not yet recruiting
  • Research Site
    Myrtle Beach, South Carolina 29572, United States
    Not yet recruiting
  • Research Site
    North Charleston, South Carolina 29405, United States
    Not yet recruiting
  • Research Site
    Memphis, Tennessee 38119, United States
    Not yet recruiting
  • Research Site
    Morristown, Tennessee 37813, United States
    Not yet recruiting
  • Research Site
    Dallas, Texas 75390, United States
    Not yet recruiting
  • Research Site
    Houston, Texas 77004, United States
    Recruiting
  • Research Site
    Houston, Texas 77040, United States
    Not yet recruiting
  • Research Site
    Houston, Texas 77079, United States
    Not yet recruiting
  • Research Site
    Katy, Texas 77450, United States
    Not yet recruiting
  • Research Site
    San Antonio, Texas 78229, United States
    Not yet recruiting
  • Research Site
    San Antonio, Texas 78231, United States
    Not yet recruiting
  • Research Site
    Sugar Land, Texas 77478, United States
    Recruiting
  • Research Site
    Weslaco, Texas 78596, United States
    Not yet recruiting
  • Research Site
    Bountiful, Utah 84010, United States
    Not yet recruiting
  • Research Site
    Salt Lake City, Utah 84124, United States
    Not yet recruiting
  • Research Site
    Falls Church, Virginia 22042, United States
    Not yet recruiting
  • Research Site
    Norfolk, Virginia 23502, United States
    Not yet recruiting
  • Research Site
    Renton, Washington 98057, United States
    Not yet recruiting
  • Research Site
    Seattle, Washington 98104, United States
    Not yet recruiting
  • Research Site
    Seattle, Washington 98105, United States
    Not yet recruiting
  • Research Site
    Morgantown, West Virginia 26505, United States
    Not yet recruiting
  • Research Site
    Buenos Aires, C1120AAC, Argentina
    Recruiting
  • Research Site
    Buenos Aires, C1425AGC, Argentina
    Recruiting
  • Research Site
    Caba, C1128AAF, Argentina
    Recruiting
  • Research Site
    Ciudad de Buenos Aires, C1094AAD, Argentina
    Recruiting
  • Research Site
    Rosario, S2000CVD, Argentina
    Recruiting
  • Research Site
    San Nicolás, B2900DMH, Argentina
    Not yet recruiting
  • Research Site
    San Vicente, 5006, Argentina
    Recruiting
  • Research Site
    Botany, 2019, Australia
    Recruiting
  • Research Site
    East Toowoomba, 4350, Australia
    Recruiting
  • Research Site
    Fitzroy, 3065, Australia
    Recruiting
  • Research Site
    Heidelberg Heights, 3081, Australia
    Recruiting
  • Research Site
    Kingswood, 2747, Australia
    Not yet recruiting
  • Research Site
    Melbourne, 3004, Australia
    Recruiting
  • Research Site
    Parkville, 3050, Australia
    Recruiting
  • Research Site
    Penrith, 2750, Australia
    Recruiting
  • Research Site
    St Leonards, 2065, Australia
    Recruiting
  • Research Site
    Brasília, 71625-009, Brazil
    Not yet recruiting
  • Research Site
    Campinas, 13060-803, Brazil
    Not yet recruiting
  • Research Site
    Curitiba, 80030-480, Brazil
    Not yet recruiting
  • Research Site
    Natal, 59020-500, Brazil
    Not yet recruiting
  • Research Site
    Porto Alegre, 90630-165, Brazil
    Not yet recruiting
  • Research Site
    São José dos Campos, 12243-280, Brazil
    Not yet recruiting
  • Research Site
    São Paulo, 04012-180, Brazil
    Not yet recruiting
  • Research Site
    Plovdiv, 4001, Bulgaria
    Recruiting
  • Research Site
    Sofia, 1407, Bulgaria
    Recruiting
  • Research Site
    Sofia, 1618, Bulgaria
    Recruiting
  • Research Site
    Sofia, 1700, Bulgaria
    Recruiting
  • Research Site
    Yambol, 8600, Bulgaria
    Recruiting
  • Research Site
    Vancouver, British Columbia V5Y 3W2, Canada
    Recruiting
  • Research Site
    Guelph, Ontario N1H 1B1, Canada
    Recruiting
  • Research Site
    Sarnia, Ontario N7T 4X3, Canada
    Recruiting
  • Research Site
    Scarborough Village, Ontario M1R 0B1, Canada
    Recruiting
  • Research Site
    Stouffville, Ontario L4A1H2, Canada
    Recruiting
  • Research Site
    Toronto, Ontario M4G3E8, Canada
    Recruiting
  • Research Site
    Toronto, Ontario M6G 1M2, Canada
    Recruiting

Showing the first 100 of 210 sites across 15 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for May 2028, 22 months after the start.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's planned 22 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2026
First posted
Jun 23, 2026
StartActual
Jul 6, 2026
Primary completionEst.
May 23, 2028
CompletionEst.
May 23, 2028
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 1 site removed. 50 sites changed recruiting status (50 now recruiting)
Show 50 sites
  • Research Site · Phoenix, United StatesNot yet recruiting→Recruiting
  • Research Site · Encinitas, United StatesNot yet recruiting→Recruiting
  • Research Site · Pomona, United StatesNot yet recruiting→Recruiting
  • Research Site · Sacramento, United StatesNot yet recruiting→Recruiting
  • Research Site · Lake City, United StatesNot yet recruiting→Recruiting
  • Research Site · Leesburg, United StatesNot yet recruiting→Recruiting
  • Research Site · Ames, United StatesNot yet recruiting→Recruiting
  • Research Site · Henderson, United StatesNot yet recruiting→Recruiting
  • Research Site · Morehead City, United StatesNot yet recruiting→Recruiting
  • Research Site · Wilmington, United StatesNot yet recruiting→Recruiting
  • Research Site · Houston, United StatesNot yet recruiting→Recruiting
  • Research Site · Sugar Land, United StatesNot yet recruiting→Recruiting
  • Research Site · Buenos Aires, ArgentinaNot yet recruiting→Recruiting
  • Research Site · Caba, ArgentinaNot yet recruiting→Recruiting
  • Research Site · Rosario, ArgentinaNot yet recruiting→Recruiting
  • Research Site · Fitzroy, AustraliaNot yet recruiting→Recruiting
  • Research Site · Heidelberg Heights, AustraliaNot yet recruiting→Recruiting
  • Research Site · Penrith, AustraliaNot yet recruiting→Recruiting
  • Research Site · Sofia, BulgariaNot yet recruiting→Recruiting
  • Research Site · Yambol, BulgariaNot yet recruiting→Recruiting
  • Research Site · Guelph, CanadaNot yet recruiting→Recruiting
  • Research Site · Toronto, CanadaNot yet recruiting→Recruiting
  • Research Site · Liangyugang, ChinaNot yet recruiting→Recruiting
  • Research Site · Nanjing, ChinaNot yet recruiting→Recruiting
  • Research Site · Tianjin, ChinaNot yet recruiting→Recruiting
  • Research Site · Berlin, GermanyNot yet recruiting→Recruiting
  • Research Site · Duisburg, GermanyNot yet recruiting→Recruiting
  • Research Site · Erlangen, GermanyNot yet recruiting→Recruiting
  • Research Site · Gladbeck, GermanyNot yet recruiting→Recruiting
  • Research Site · Hamburg, GermanyNot yet recruiting→Recruiting
  • …and 20 more on the registry record
Show 2 added (2 United States)
  • Research Site · Rockville, United States
  • Research Site · Falls Church, United States
Show 1 removed
  • Research Site · Leesburg, United States
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    2 sites added, 1 site removed. 55 sites changed recruiting status (55 now recruiting)
    Show 55 sites
    • Research Site · Phoenix, United StatesNot yet recruiting→Recruiting
    • Research Site · Encinitas, United StatesNot yet recruiting→Recruiting
    • Research Site · Pomona, United StatesNot yet recruiting→Recruiting
    • Research Site · Sacramento, United StatesNot yet recruiting→Recruiting
    • Research Site · Lake City, United StatesNot yet recruiting→Recruiting
    • Research Site · Leesburg, United StatesNot yet recruiting→Recruiting
    • Research Site · Ames, United StatesNot yet recruiting→Recruiting
    • Research Site · Henderson, United StatesNot yet recruiting→Recruiting
    • Research Site · Morehead City, United StatesNot yet recruiting→Recruiting
    • Research Site · Wilmington, United StatesNot yet recruiting→Recruiting
    • Research Site · Houston, United StatesNot yet recruiting→Recruiting
    • Research Site · Sugar Land, United StatesNot yet recruiting→Recruiting
    • Research Site · Buenos Aires, ArgentinaNot yet recruiting→Recruiting
    • Research Site · Caba, ArgentinaNot yet recruiting→Recruiting
    • Research Site · Rosario, ArgentinaNot yet recruiting→Recruiting
    • Research Site · Fitzroy, AustraliaNot yet recruiting→Recruiting
    • Research Site · Heidelberg Heights, AustraliaNot yet recruiting→Recruiting
    • Research Site · Penrith, AustraliaNot yet recruiting→Recruiting
    • Research Site · Sofia, BulgariaNot yet recruiting→Recruiting
    • Research Site · Sofia, BulgariaNot yet recruiting→Recruiting
    • Research Site · Yambol, BulgariaNot yet recruiting→Recruiting
    • Research Site · Guelph, CanadaNot yet recruiting→Recruiting
    • Research Site · Toronto, CanadaNot yet recruiting→Recruiting
    • Research Site · Liangyugang, ChinaNot yet recruiting→Recruiting
    • Research Site · Nanjing, ChinaNot yet recruiting→Recruiting
    • Research Site · Tianjin, ChinaNot yet recruiting→Recruiting
    • Research Site · Berlin, GermanyNot yet recruiting→Recruiting
    • Research Site · Duisburg, GermanyNot yet recruiting→Recruiting
    • Research Site · Erlangen, GermanyNot yet recruiting→Recruiting
    • Research Site · Gladbeck, GermanyNot yet recruiting→Recruiting
    • …and 25 more on the registry record
    Show 2 added (2 United States)
    • Research Site · Rockville, United States
    • Research Site · Falls Church, United States
    Show 1 removed
    • Research Site · Leesburg, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07662213
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 23, 2026
Start date
Jul 6, 2026
Primary completion
May 23, 2028 (estimated)
Completion
May 23, 2028 (estimated)
Last update
Oct 22, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elecoglipron

Start the discussion